At the time of writing, Palisade Bio Inc [PALI] stock is trading at $6.03, up 8.80%. An important factor to consider is whether the stock is rising or falling in short-term value. The PALI shares have gain 3.02% over the last week, with a monthly amount glided 2.71%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 3, April 2024, Palisade Bio Announces 1-for-15 Reverse Stock Split. In a post published today on Yahoo Finance, Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced a 1-for-15 reverse split of its common stock, par value $0.01 (“Common Stock”), effective at 5:00 PM ET on Friday April 5, 2024. Beginning on Monday, April 8, 2024, the Company’s Common Stock will continue to trade on The Nasdaq Capital Market (“Nasdaq”) on a split adjusted basis under the trading symbol “PALI,” but will trade under the following new CUSIP number starting April 8, 2024: 696389402.
From an analyst’s perspective:
For the past year, the stock price of Palisade Bio Inc fluctuated between $5.40 and $36.60. Currently, Wall Street analysts expect the stock to reach $1.5 within the next 12 months. Palisade Bio Inc [NASDAQ: PALI] shares were valued at $6.03 at the most recent close of the market. An investor can expect a potential drop of -75.12% based on the average PALI price forecast.
Analyzing the PALI fundamentals
Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -55.06%, Pretax Profit Margin comes in at -52.2%, and Net Profit Margin reading is -47.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.69, Equity is -0.84 and Total Capital is -0.95. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.9200 points at the first support level, and at 3.8200 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.2100, and for the 2nd resistance point, it is at 8.3900.
Palisade Bio Inc [PALI] reported earnings per share of -$0.43 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.34/share, meaning a difference of -$0.09 and a surprise factor of -26.50%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.44 per share as compared to estimates of -$0.39 per share, a difference of -$0.05 representing a surprise of -12.80%.
Ratios To Look Out For
It is important to note that Palisade Bio Inc [NASDAQ:PALI] has a current ratio of 5.11. On the other hand, the Quick Ratio is 5.11, and the Cash Ratio is 5.78. Considering the valuation of this stock, the price to sales ratio is 223.83, the price to book ratio is 0.33.
Transactions by insiders
Recent insider trading involved Finley John David, CEO, CFO, Director, that happened on Feb 06 ’24 when 10000.0 shares were purchased. Director, Williams Donald Allen completed a deal on Jan 31 ’24 to buy 10000.0 shares. Meanwhile, CEO, CFO, Director Finley John David bought 10000.0 shares on Jan 31 ’24.
